SelectION is a clinical-stage biopharmaceutical company developing novel peptide therapies for autoimmune diseases and selecting cancer indications by targeting autoreactive, chronically activated T cells. It has established a technology platform to develop potent and highly selective peptide blockers for ion channels involved in various diseases.